A method for identifying the financial burden of hospitalized infants on families

Value in Health

Volumn 5, Issue 1, 2002, Pages 55-59

  Leader, S ^a   Jacobson, P ^b   Marcin, J ^c   Vardis, R ^d   Sorrentino, M ^a   Murray, D ^e  

^a MEDIMMUNE   (United States)

^b Rush Children's Hospital and Rush University Medical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Bellin Hospital   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cost; Methods; Prematurity; Respiratory syncytial virus

Indexed keywords

ARTICLE; CHILD HOSPITALIZATION; CLINICAL ARTICLE; FINANCIAL MANAGEMENT; HOSPITAL COST; HUMAN; INFANT; INTENSIVE CARE UNIT; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

EID: 0036173821     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.51076.x     Document Type: Article

References (10)

1. Update. Respiratory syncytial virus activity - United States, 1998-1999 season
2. Bronchiolitis-associated hospitalizations among US Children. 1980-96
3. Prevention of RSV infections: Indications for use of palivizumab and update on the use of RSV-IGIV
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
5. Effectiveness of Palivizumab - Evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season
6. Cost-effectiveness of respiratory syncytial virus prophylaxis among pre-term infants
7. Respiratory syncytial virus and premature infants born at 32 weeks gestation or earlier
8. Framing and designing the cost-effectiveness analysis
9. Development of local guidelines for prevention of respiratory syncytial viral infections
10. Healthcare resource utilization and costs of RSV-related hospitalizations